Evidence map›Paper›PMID 38821916›Full record

ArticleNature communications2024

ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression.

Huan Zhang, Yan Sun, Zhaokai Wang, Xiaoju Huang, Lu Tang, Ke Jiang, Xin Jin

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Interplay of RNA mFASEB bioAdvances · 2026
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huan ZhangDepartment of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.ORCID http://orcid.org/0009-0005-4918-5194
Yan SunDepartment of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Zhaokai WangDepartment of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Xiaoju HuangCancer center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Lu TangInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. lu_tang@hust.edu.cn.ORCID http://orcid.org/0009-0009-1590-2465
Ke JiangDepartment of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. kkkj_77@aliyun.com.ORCID http://orcid.org/0000-0001-8925-571X
Xin JinDepartment of Urology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. jinxinxy2@csu.edu.cn.ORCID http://orcid.org/0000-0001-6461-6005

Funding

China Postdoctoral Science Foundation No.2023M731220National Natural Science Foundation of China (National Science Foundation of China) No. 82073321National Natural Science Foundation of China (National Science Foundation of China) No. 82100190National Natural Science Foundation of China (National Science Foundation of China) No.82272910National Natural Science Foundation of China (National Science Foundation of China) No. 82303826
6 · The paper itself

Abstract

Post-translational modifications of proteins in malignant transformation and tumor maintenance of pancreatic ductal adenocarcinoma (PDAC) in the context of KRAS signaling remain poorly understood. Here, we use the KPC mouse model to examine the effect of palmitoylation on pancreatic cancer progression. ZDHHC20, upregulated by KRAS, is abnormally overexpressed and associated with poor prognosis in patients with pancreatic cancer. Dysregulation of ZDHHC20 promotes pancreatic cancer progression in a palmitoylation-dependent manner. ZDHHC20 inhibits the chaperone-mediated autophagic degradation of YTHDF3 through S-palmitoylation of Cys474, which can result in abnormal accumulation of the oncogenic product MYC and thereby promote the malignant phenotypes of cancer cells. Further, we design a biologically active YTHDF3-derived peptide to competitively inhibit YTHDF3 palmitoylation mediated by ZDHHC20, which in turn downregulates MYC expression and inhibits the progression of KRAS mutant pancreatic cancer. Thus, these findings highlight the therapeutic potential of targeting the ZDHHC20-YTHDF3-MYC signaling axis in pancreatic cancer.

Indexed as

AcyltransferasesCarcinoma, Pancreatic DuctalGene Expression Regulation, NeoplasticLipoylationPancreatic NeoplasmsProto-Oncogene Proteins c-mycAnimalsCell Line, TumorDisease ProgressionFemaleHumansMaleMiceProto-Oncogene Proteins p21(ras)RNA-Binding ProteinsRNA, MessengerAcyltransferasesKRAS protein, humanMYC protein, humanProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)RNA-Binding ProteinsRNA, MessengerYTHDF3 protein, humanZDHHC20 protein, human

Identifiers

PMID38821916
PMCPMC11143236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.